Startups
ProNovo Therapeutics
Biotechnology company developing precision medicines for neuropsychiatric disorders, with initial preclinical programs for major depressive disorder and schizophrenia. Its PNV-001 program pursues a novel therapeutic mechanism for depression, while PNV-002 targets an emerging mechanism for schizophrenia. ProNovo combines research into genetic susceptibility, disease biology, therapeutic mechanisms and prognostic biomarkers to identify and develop drug candidates for patients whose needs are not met by current psychiatric treatments. Founded by researchers and drug-development executives with experience in molecular neurotherapeutics, CNS research and small-molecule development, it is advancing its pipeline toward clinical testing. The company’s candidates remain in preclinical development.